For research use only. Not for therapeutic Use.
Deferoxamine（Cat No.:I006422）is a potent iron-chelating agent widely used in treating iron overload disorders, such as those in patients with thalassemia receiving frequent blood transfusions. By binding excess iron in the bloodstream, deferoxamine prevents iron from accumulating in vital organs, reducing the risk of damage to the heart, liver, and endocrine glands. It also has applications in managing aluminum toxicity in patients with chronic kidney disease. Administered via injection, deferoxamine is essential in preventing complications related to iron toxicity, thereby improving long-term health outcomes in affected patients.
| Catalog Number | I006422 |
| CAS Number | 70-51-9 |
| Synonyms | Deferoxamine; Deferoxaminum; Deferoxamin; Desferin; Deferrioxamine B; DFOA, Desferal,;N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N/’-(5-aminopentyl)-N/’-hydroxybutanediamide |
| Molecular Formula | C25H48N6O8 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide |
| InChI | InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34) |
| InChIKey | UBQYURCVBFRUQT-UHFFFAOYSA-N |
| SMILES | CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O |
| Reference | </br>1:Effects of deferoxamine mesylate on hematoma and perihematoma edema after traumatic intracerebral hemorrhage. Yu J, Yuan Q, Sun YR, Wu X, Du ZY, Li ZQ, Wu XH, Zhou LF, Wu G, Hu J.J Neurotrauma. 2017 May 2. doi: 10.1089/neu.2017.5033. [Epub ahead of print] PMID: 28462672 </br>2:Deferoxamine: potential novel topical therapeutic for chronic wounds. Tchanque-Fossuo CN, Dahle SE, Buchman SR, Rivkah Isseroff R.Br J Dermatol. 2017 Apr;176(4):1056-1059. doi: 10.1111/bjd.14956. No abstract available. PMID: 28418133 </br>3:Deferoxamine-conjugated AgInS<sub>2</sub> nanoparticles as new nanodrug for synergistic therapy for hepatocellular carcinoma. Phiwchai I, Thongtem T, Thongtem S, Pilapong C.Int J Pharm. 2017 May 30;524(1-2):30-40. doi: 10.1016/j.ijpharm.2017.03.058. Epub 2017 Mar 28. PMID: 28359812 </br>4:Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination. Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.Drug Res (Stuttg). 2017 Mar 20. doi: 10.1055/s-0043-102691. [Epub ahead of print] PMID: 28320041 </br>5:Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia. Al-Kuraishy HM, Al-Gareeb AI.Asian J Transfus Sci. 2017 Jan-Jun;11(1):13-17. doi: 10.4103/0973-6247.200768. PMID: 28316434 Free PMC Article</br>6:Deferoxamine-activated hypoxia-inducible factor-1 restores cardioprotective effects of sevoflurane postconditioning in diabetic rats. Xie P, Yang L, Talaiti A, Wu JJ, Yu J, Yu T, Wang HY, Huang B, Wu Q, Maimaitili Y, Wang J, Ma HP, Yang YN, Zheng H.Acta Physiol (Oxf). 2017 Mar 17. doi: 10.1111/apha.12874. [Epub ahead of print] PMID: 28316125 </br>7:Effects of deferoxamine on blood-brain barrier disruption after subarachnoid hemorrhage. Li Y, Yang H, Ni W, Gu Y.PLoS One. 2017 Mar 1;12(3):e0172784. doi: 10.1371/journal.pone.0172784. eCollection 2017. PMID: 28249040 Free PMC Article</br>8:Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Duscher D, Januszyk M, Maan ZN, Whittam AJ, Hu MS, Walmsley GG, Dong Y, Khong SM, Longaker MT, Gurtner GC.Plast Reconstr Surg. 2017 Mar;139(3):695e-706e. doi: 10.1097/PRS.0000000000003072. PMID: 28234841 </br>9:Porphyria Cutanea Tarda in a Patient with End-Stage Renal Disease: A Case of Successful Treatment with Deferoxamine and Ferric Carboxymaltose. Rodrigues N, Caeiro F, Santana A, Mendes T, Lopes L.Case Rep Nephrol. 2017;2017:4591871. doi: 10.1155/2017/4591871. Epub 2017 Jan 22. PMID: 28210512 Free PMC Article</br>10:K. pneumoniae liver abscess following deferoxamine subcutaneous self-injection. Furlan L, Graziadei G, Colombo G, Forzenigo LV, Solbiati M.Am J Hematol. 2017 May;92(5):480-481. doi: 10.1002/ajh.24675. Epub 2017 Mar 10. No abstract available. PMID: 28188653 |
